

# Errata Corrige

Table I – Main characteristics and results of the selected studies.

Authors	Drugs (N. of exposed)	Rate of spontaneous abortion reported in the study***
<p><b>I due punti elenco all'interno del quadrato in alto sono in realtà un solo punto elenco, che comincia con "Fluoxetine..."</b></p>		
Studies reporting statistically significant rates of SA in exposed		
Pastuszak <i>et al.</i> , 1993	Fluoxetine (128; 25.8 mg - mean daily dose); TCAs (74)	100
Chun-Fai-Chan <i>et al.</i> , 2005	Bupropion (136; 91 for depression, 45 for smoking cessation)	65.9
Yaris <i>et al.</i> , 2005	SSRIs (74), MAOIs (7), Bupropion (1)	71.5
<p><b>Questo punto elenco all'interno del quadrato sottostante va trasferito al di sotto della linea continua, nella riga di tabella relativa al lavoro di Chun Fai-Chan <i>et al.</i>, 2005</b></p>		
Studies reporting statistically not significant differences in the rate of SA in exposed vs. unexposed controls		
Chambers <i>et al.</i> , 1996	Fluoxetine (228; 28 mg - mean daily dose)	76.9
Djulius <i>et al.</i> , 2006	Mirtazapine (104; 30.0 - mean daily dose)	100
Eimanson <i>et al.</i> , 2001a	Venlafaxine (150; 75.0 - modal dose)	NS
Eimanson <i>et al.</i> , 2003	Trazodone or nefazodone (147)	100
Goldstein <i>et al.</i> , 1997	Fluoxetine (77)	100
Kulin <i>et al.</i> , 1998	SSRIs (267)	100
Sivojelezova <i>et al.</i> , 2005	Citalopram (132; 0.345 mg/kg/d - median dose)	93.5 93.5
<p><b>Rate of spontaneous abortion reported in the study***</b></p> <ul style="list-style-type: none"> <li>Fluoxetine (13.5% [2.0]), TCAs (12.2% [1.8]), Fluoxetine (14.8% [1.9]), NTDs (7.8%) (p=0.03), NTDs (6.8%) (p=ns), Bupropion as a whole (14.7% [3.3]), NTDs (4.5%) (p=0.009).</li> <li>Bupropion for depression (15.4% [3.4]), bupropion for smoking cessation (16.2% [3.6]), NTDs (4.5%) (p=0.010).</li> <li>Bupropion (15.4% [2.3]), OADs (12.3%), NTDs (6.7%) (p=ns).</li> <li>ADs (8.5% [2.4]), untreated group (3.6%) (p&lt;0.001).</li> </ul>		
Fluoxetine (10.0% [1.2]), NTDs (8.5%).		
Mirtazapine (19.0% [1.7]), OADs (17.0%), NTDs (11.0%).		
Venlafaxine (12.0% [1.6]), OADs (10.7%), NTDs (7.3%).		
Trazodone or nefazodone (19.0% [2.3]), OADs (11.6%), NTDs group (8.2%).		
Fluoxetine (24.3% [0.9]), placebo (25.0%).		
SSRIs (11.2% [1.4]), NTDs (7.9%).		
Citalopram (11.0% [1.1]), SSRIs (10.0%), NTDs (10.0%).		

\*: NTDs: non-teratogenic drugs; OADs: other antidepressants; TCAs: tricyclic antidepressants.

\*\*: NS: Non specified

\*\*\*: SA relative risk for study subjects with respect to controls not exposed to ADs in brackets.

Desideriamo segnalare ai lettori che nel numero 3 del 2009 la Tabella I dell'articolo "Is the exposure to antidepressant drugs in early pregnancy..." (18(3): 240-247) è stata involontariamente sbagliata.

Riportiamo di seguito i passaggi di interesse evidenziati in neretto.